{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein&page=12",
    "query": {
      "intervention": "Protein",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 19078,
    "total_pages": 1908,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T10:58:34.250Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01779024",
      "title": "Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "fMRI",
        "Alcohol Drinking",
        "Alcoholism"
      ],
      "interventions": [
        {
          "name": "Ghrelin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "fMRI",
          "type": "PROCEDURE"
        },
        {
          "name": "Alcohol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 17,
      "start_date": "2012-12-13",
      "completion_date": "2017-06-01",
      "has_results": true,
      "last_update_posted_date": "2018-08-03",
      "last_synced_at": "2026-10-18T10:58:34.250Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01779024"
    },
    {
      "nct_id": "NCT02299882",
      "title": "Surgical Infection Rates With Adjunct Vancomycin Compared to Standard Peri-Operative IV Antibiotics",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lumbar Pain"
      ],
      "interventions": [
        {
          "name": "Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corewell Health West",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 700,
      "start_date": "2012-08",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2014-11-24",
      "last_synced_at": "2026-10-18T10:58:34.250Z",
      "location_count": 1,
      "location_summary": "Grand Rapids, Michigan",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02299882"
    },
    {
      "nct_id": "NCT06785324",
      "title": "Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Philadelphia Chromosome Negative",
        "B Cell Acute Lymphoblastic Leukemia (B-ALL)",
        "B-ALL"
      ],
      "interventions": [
        {
          "name": "Nutrition Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Exercise intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-05-12",
      "completion_date": "2027-11-06",
      "has_results": false,
      "last_update_posted_date": "2025-06-19",
      "last_synced_at": "2026-10-18T10:58:34.250Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06785324"
    },
    {
      "nct_id": "NCT01756924",
      "title": "Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prosthetic Joint Infections of Hip",
        "Prosthetic Joint Infections of Knee",
        "Infected Spacers"
      ],
      "interventions": [
        {
          "name": "CEM-102",
          "type": "DRUG"
        },
        {
          "name": "IV or Oral standard of care antibiotics",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arrevus Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2012-12",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2019-04-19",
      "last_synced_at": "2026-10-18T10:58:34.250Z",
      "location_count": 13,
      "location_summary": "Sarasota, Florida • Tamarac, Florida • Savannah, Georgia + 8 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01756924"
    },
    {
      "nct_id": "NCT05268224",
      "title": "A Tear-based, Lab-developed Test for Breast Cancer for Women With Dense Breast Tissue",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer Screening"
      ],
      "interventions": [
        {
          "name": "Schirmer Strip",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Namida Lab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 100 Years · Female only"
      },
      "enrollment_count": 1500,
      "start_date": "2021-10-01",
      "completion_date": "2024-10",
      "has_results": false,
      "last_update_posted_date": "2023-12-11",
      "last_synced_at": "2026-10-18T10:58:34.250Z",
      "location_count": 1,
      "location_summary": "Fayetteville, Arkansas",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05268224"
    },
    {
      "nct_id": "NCT03122223",
      "title": "Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "ALVAC-HIV (vCP2438)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent subtype C gp120/MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent subtype C gp120/AS01(B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 160,
      "start_date": "2018-01-16",
      "completion_date": "2020-07-30",
      "has_results": true,
      "last_update_posted_date": "2023-03-14",
      "last_synced_at": "2026-10-18T10:58:34.250Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03122223"
    },
    {
      "nct_id": "NCT01061515",
      "title": "Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma"
      ],
      "interventions": [
        {
          "name": "Intraperitoneal Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2011-05-10",
      "completion_date": "2027-09-27",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-18T10:58:34.250Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01061515"
    },
    {
      "nct_id": "NCT00288015",
      "title": "Bevacizumab in Treating Patients With Angiosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2005-10",
      "completion_date": "2016-11-10",
      "has_results": true,
      "last_update_posted_date": "2018-06-25",
      "last_synced_at": "2026-10-18T10:58:34.250Z",
      "location_count": 5,
      "location_summary": "La Jolla, California • Chicago, Illinois • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00288015"
    },
    {
      "nct_id": "NCT00184015",
      "title": "Bortezomib and Bevacizumab (\"BB-mib-mab\") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "Bevacizumab and Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2005-08-18",
      "completion_date": "2018-08-21",
      "has_results": false,
      "last_update_posted_date": "2017-04-11",
      "last_synced_at": "2026-10-18T10:58:34.250Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00184015"
    },
    {
      "nct_id": "NCT04317040",
      "title": "Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus Disease 2019 (COVID-19)"
      ],
      "interventions": [
        {
          "name": "Efprezimod alfa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2020-04-24",
      "completion_date": "2020-10-20",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-10-18T10:58:34.250Z",
      "location_count": 10,
      "location_summary": "Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Annapolis",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04317040"
    }
  ]
}